High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Cañadas, Israel
- dc.contributor.author Taus, Álvaro
- dc.contributor.author González, Iria
- dc.contributor.author Villanueva, Xavie
- dc.contributor.author Gimeno, Javier
- dc.contributor.author Pijuan, Lara
- dc.contributor.author Dómine, Manuel
- dc.contributor.author Sánchez-Font, Albert
- dc.contributor.author Vollmer, Ivan
- dc.contributor.author Menéndez, Silvia
- dc.contributor.author Arpí, Oriol
- dc.contributor.author Mojal, Sergio
- dc.contributor.author Rojo, Federico
- dc.contributor.author Rovira, Ana
- dc.contributor.author Albanell, Joan
- dc.contributor.author Arriola Aperribay, Edurne
- dc.date.accessioned 2023-06-06T10:24:14Z
- dc.date.available 2023-06-06T10:24:14Z
- dc.date.issued 2014
- dc.description.abstract We have previously shown that Met activation through the hepatocyte growth factor (HGF) increases tumorogenesis, induces epithelial-to-mesenchymal transition (EMT) and chemoresistance in SCLC. We sought to evaluate circulating HGF levels in SCLC patients and assess correlation with outcome and EMT features in the tumor. Serum samples from patients with SCLC were prospectively obtained at diagnosis, response evaluation and progression. HGF serum (sHGF) was quantified by ELISA. EMT markers and p-Met/Met were assayed by immunohistochemistry in tumor samples. Clinical data were prospectively recorder. One-hundred twelve patients were included. High baseline levels of sHGF were associated with shorter overall survival (p=0.007) and remained independently associated with survival in the multivariate analysis (p=0.016). For stage IV patients, an increase of sHGF levels at response evaluation (p=0.042) and at progression (p=0.003) were associated with poor outcome. sHGF levels were associated (p<0.05) with a mesenchymal phenotype in the tumor. In conclusion, high sHGF at diagnosis and increases during the course of the disease predict for poor outcome in SCLC patients and associate with EMT in the tumor. These data provide novel evidence on a role of sHGF in the adverse clinical behavior of SCLC and support testing Met inhibitors in patients with high sHGF.
- dc.format.mimetype application/pdf
- dc.identifier.citation Cañadas I, Taus Á, González I, Villanueva X, Gimeno J, Pijuan L, et al. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 2014 Jun 20;5(14):5246-56. DOI: 10.18632/oncotarget.2124
- dc.identifier.doi http://dx.doi.org/10.18632/oncotarget.2124
- dc.identifier.issn 1949-2553
- dc.identifier.uri http://hdl.handle.net/10230/57084
- dc.language.iso eng
- dc.publisher Impact Journal
- dc.relation.ispartof Oncotarget. 2014 Jun 20;5(14):5246-56
- dc.rights All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/3.0/
- dc.subject.keyword Small cell lung cancer
- dc.subject.keyword Hepatocyte growth factor
- dc.subject.keyword Met
- dc.subject.keyword Epithelial to mesenchymal transition
- dc.subject.keyword Chemoresistance
- dc.title High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion